ASCITES is a problem frequently encountered and often unsatisfactorily treated. An adjunct in the therapy of ascites has been tried in a limited number of cases and has seemed sufficiently helpful to ...

"Ascites in decompensated cirrhosis is a poor prognostic indicator, with a 50% 2-year survival, worsening significantly to 20% to 50% at 1 year when the ascites becomes refractory to medical therapy." ...

THE problem of the accumulation of fluid in the peritoneal cavity in association with cirrhosis of the liver has for many years presented a challenge to the surgeon, since it has always been tempting ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of ...

DelveInsight’s, “Malignant Ascites Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the ...

Ascites is the most common complication of liver cirrhosis, and it develops as a consequence of portal hypertension and splanchnic vasodilatation. Depending on severity, management of ascites consists ...

Challenges in developing drugs for pancreatic ductal adenocarcinoma (PDAC) include obtaining metastatic cancer tissue for research and validating biomarkers predicative for personalised therapeutic ...

BioVie’s stock has moved up considerably over the past 9 months in light of promising Alzheimer’s data. BioVie Day and full Phase 2 Parkinson’s trial results are scheduled for this month. BioVie has ...

The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The ascites ...